The DOI matches its Crossref record.
Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress
Abstract
Clusterin (apoJ), a multifunctional apolipoprotein made by cells in the brain and many other locations, is associated with aggregated amyloid beta-peptide (A beta) in senile and diffuse plaques of Alzheimer's disease (AD). We observed that purified human serum clusterin partially blocked the aggregation of synthetic A beta 1-42, as shown by centrifugal assays (14,000g x 10 min) and by atomic force (scanning probe) microscopy. Slowly sedimenting A beta complexes were formed in the presence of clusterin, which included aggregates > 200 kDa that resist dissociation by low concentrations of SDS. Clusterin enhanced the oxidative stress caused by A beta, as assayed by oxidative stress in PC12 cells with MTT, which is widely used to estimate neurotoxicity. These indications of enhanced neurotoxicity by the MTT assay were observed in the highly aggregated rapidly sedimenting fraction, but also in more slowly sedimenting "soluble" forms. This novel activity of slowly sedimenting A beta may enhance the neurotoxicity of A beta deposits in AD brains, because soluble complexes have a potential for diffusing to damage distal neurons.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“oligomeric Aβ rather than fibril Aβ is regarded as the toxic species of this peptide [143,144,145,146].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [143]
In the citing paper
“Furthermore, APOE and CLU have been shown to cooperate in suppressing Aβ deposition 33 and APOE and CLU may critically modify Aβ clearance at the blood brain barrier”
From Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2009) · cites this paper as [33]
In the citing paper
“A 1-42 aged according to this protocol is a mixture of fibrils and soluble globular aggregates, and is active to astrocytes (37,38) and toxic to neurons (26,27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“In vitro, apoE and apoJ form stable complexes with A (11, 16 -20), alter the aggregation of various A peptides (21)(22)(23), and affect A neurotoxicity (24 -27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“ApoJ has been shown to potentiate the formation of a neurotoxic species of A (26,27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“ApoE, apoJ, and most recently ␣ 2 -macroglobulin have been shown to form a complex with A that may facilitate clearance of the peptide (25-27, 50, 51).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“CLU levels also appear to affect aggregation of Aβ (Oda, et al., 1995,Wilson, et al., 2008)”
From A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin (2016) · cites this paper as Oda, et al., 1995
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 301–350 of 350
Laslo, A., Boghițoiu, T., Chinezu, L., Manu, D. R., Ivănescu, A. D., Cordoș, B. A., Wilson, M. R., Bănescu, C. V., Fryer, J. D., Verma, A. K., et al. (2025) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.70037 · Cited by 2
El péptido β-amiloide: mecanismos de neurotoxicidad. neuroprotección por antioxidantes y estrógenos
López, F. J. M. (2001) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(01)74694-x · Cited by 2
Sun, H.-Y., Duan, S., Qin, N., Pi, J., Sun, P., Huang, Q., Wang, H., Huang, M.-C., Wang, S.-T., Liu, W., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06801-7 · Cited by 2
12th International Conference on Alzheimer's Disease (ICAD), Vienna, Austria
Strobel, G. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1250 · Cited by 2
Preparation and Structural Characterization of Pre-fibrillar Assemblies of Amyloidogenic Proteins
Frydman‐Marom, A., Bram, Y., & Gazit, E. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_3 · Cited by 2
Tam, J. H. K., & Pasternak, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00004-5 · Cited by 2
Dabbs, R. A., Wyatt, A. R., Yerbury, J. J., Ecroyd, H. W., & Wilson, M. R. (2010) · Topics in current chemistry · doi:10.1007/128_2010_85 · Cited by 2
Microglial and Astrocytic Reactions in Alzheimer’s Disease
Walker, D. G., & Beach, T. G. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-105-3_19 · Cited by 2
Volkova, T. D., Avetisyan, A. V., Koroev, D. O., Kamynina, A. V., Balasanyants, S. M., Simonyan, R. A., & Volpina, O. M. (2022) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162022040197 · Cited by 1
Trait, State, and Mechanism: Looking Back, Looking Forward, and Understanding Why
Lovestone, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129014 · Cited by 1
Neurotoxicity of the Alzheimer’s β-Amyloid Peptide
Howlett, D. R. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-888-5_6 · Cited by 1
Non‐fibrillar β‐amyloid exerts toxic effect on neuronal cells
Kim, H., & Hong, S. (2001) · Korean Journal of Biological Sciences · doi:10.1080/12265071.2001.9647595 · Cited by 1
The Role of Aβ in the Development of Alzheimer’s Disease and its Mechanisms
Jin, Y. (2020) · E3S Web of Conferences · doi:10.1051/e3sconf/202021803041 · Cited by 1
Attack of the Oligomers – Alpha-synuclein amyloid oligomers and their pathogenic roles
Gruschus, J. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85707-9.00001-0 · Cited by 1
Glial Hyperactivity During Aging as a Neuroinflammatory Process
Finch, C. E., Morgan, T. E., Xie, Z., Stone, D., Lanzrein, A.-S., & Rozovsky, I. (2000) · Research and perspectives in neurosciences · doi:10.1007/978-3-642-59643-8_5 · Cited by 1
Self-citationCurrent and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
Rukhsana Sultana, A., Poon, H. F., & Butterfield, D. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_15 · Cited by 1
Apolipoprotein E: Structural and Functional Interactions with Amyloid β
Stine, W. B., & LaDu, M. J. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch10 · Cited by 1
Self-citationReif, B., & Narayanan, S. (2006) · Springer eBooks · doi:10.1007/128_066 · Cited by 1
The functional studies of amyloid fibrils and their toxicity
Elias, A. K. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/5837c388b5509 · Cited by 1
Sahoo, B. R., Bekier, M. E., Liu, Z., Kocman, V., Stoddard, A. K., Anantharamaiah, G. M., Nowick, J. S., Fierke, C. A., Wang, Y., & Ramamoorthy, A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/722983 · Cited by 1
Vascular Transport of Alzheimer’s Amyloid β Peptides and Apolipoproteins
Zloković, B. V., Ghiso, J. A., & Frangione, B. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_20 · Cited by 1
Signaling Mechanisms that Mediate Aβ Induced Neuronal Dysfunction
Cotman, C. W., & Busciglio, J. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_8
Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease
Golde, T. E. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70052-8
Computational Studies of Folding and Assembly of Amyloidogenic Proteins
Rao, J. S., Urbanc, B., & Cruz, L. (2012) · doi:10.1002/9781118183373.ch16
Wang, L., & Campioni, S. (2011) · InTech eBooks · doi:10.5772/20922
Protein misfolding and amyloid formation
Nerelius, C. (2009) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences))
The role of clusterin (CLU) in extracellular protein folding quality control.
Wyatt, A. R. (2009) · Research Online (University of Wollongong)
Role and regulation of early complement activation products in Alzheimer’s disease
Veerhuis, R., Muiswinkel, F. L. V., Hack, C. E., & Eikelenboom, P. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_3
On keys and correlations in Alzheimer's disease
Potter, H. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00177-7
Costa, D. A. (2005) · Digital Commons - University of South Florida (University of South Florida)
Synthesis, Fate, and Proposed Function of Clusterin (SGP-2) in the Testis
Bailey, R. W., Clark, A., Lymar, E. S., Tribley, W. A., & Griswold, M. D. (2000) · Springer eBooks · doi:10.1007/978-1-4612-2106-7_7
Pancreatic Islet Amyloid Polypeptide Membrane Binding and Permeabilization.
Lee, E. L. (2009) · Deep Blue (University of Michigan)
Studying Amyloid b-Protein Assembly
Maji, S. K., Lazo, N. D., Fradinger, E. A., & Teplow, D. B. (2004) · CRC Press eBooks · doi:10.1201/9780203492185.ch7
Protein Misfolding and Amyloid Formation in Alzheimer’s Disease
Tayubi, I. A., Firoz, A., & Malik, A. (2015) · Springer eBooks · doi:10.1007/978-81-322-2467-9_7
Nutrition, Inflammation, and Infection in the Genomics of Lifespan
Finch, C. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11297-8
Self-citationFeng, L. (2019) · Research Online (University of Wollongong)
Nelsestuen, G. L., & McDonald, J. F. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0142
(2007) · Elsevier eBooks · doi:10.1016/b978-012373657-4/50008-8
Aß Toxicity in Alzheimer’s Disease
Klein, W. L. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_1 · Cited by 14
Tang, L., Wang, Z.-B., Ma, L.-Z., Cao, X., Tan, L., & Tan, M.-S. (2023) · Figshare · doi:10.6084/m9.figshare.22600172
Additional file 1 of Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation
Wojtas, A., Carlomagno, Y., Sens, J. P., Kang, S. S., Jensen, T. D., Kurti, A., Baker, K. E., Berry, T. J., Phillips, V. R., Castanedes, M. C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13316710
Sharif, N., Bibi, A., Sadiq, R., Ullah, I., Rauf, A., Arshad, M. T., Bashir, S., Zamir, H., Gull, S., Anwar, T., et al. (2025) · Scientifica · doi:10.1155/sci5/1132636
Mahmoudi, A.-E.-R. (2015) · theses.fr (ABES) · doi:10.70675/5f05520ez1713z4991za6c8z055ab117e2bb
Abuhassan, Q., Ardah, M. T., Menon, S. V., Maharana, L., Inbathamizh, L., Mukherjee, G., Sinha, A., Khodzhiyeva, S., & Initiative, A. D. N. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03070-4
de Campos, R. M., Carraro, M. F., Bitencourt, A. L. B., Jerisha, J., Ayon, N. J., Juska, V. B., Pinheiro, N. R., Johnson, E. A., Nowar, R., McGee, J. P., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113499
Newman, S. F. (2009) · UKnowledge (University of Kentucky)
Shinpo (2000) · doi:10.1002/1097-4547(20001101)62:3
Metadata
- Authors
- Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., Krafft, G. A., & Finch, C. E.
- Affiliations
- Northwestern University (US)
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 1995-11
- Volume
- 136
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W1584774790
- Cited by
- 352
- References
- 0
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 9 · 2016: 10 · 2015: 10 · 2014: 10 · 2013: 12 · 2012: 17
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r35ag007909-03)
- National Institute on Aging (AG-1048, AG7909)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Clusterin in disease pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- clusterin, amyloid-beta 42, amyloid fibril formation, Alzheimer's disease, oxidative stress, neurotoxicity, amyloid plaques, diffuse plaques, PC12 cells, MTT assay
- MeSH terms
- Alzheimer Disease, Animals, Complement Inactivator Proteins, Dose-Response Relationship, Drug, Glycoproteins, Humans, Immunohistochemistry, Radioligand Assay, Sucrose, Amyloid beta-Protein Precursor, PC12 Cells, Oxidative Stress, Molecular Chaperones, Clusterin, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
